|
March 18, 2009
|
Dr. Bruce S. Lamb Joins Affinergy as Senior VP of Research & Development
RESEARCH TRIANGLE PARK, N.C., March 18, 2009 - Affinergy, Inc., a Duke University spinout with a proprietary site-specific biological delivery system, announced today that Dr. Bruce S. Lamb has joined its executive team as Senior Vice President for Research & Development. Dr. Lamb has 23 years leadership experience in development of multiple surgical products such as biologic hernia meshes, wound care products, and other biosurgical products. Most recently, Dr. Lamb served as Senior VP of Development and Regulatory Affairs at LifeCell, Inc. which was acquired in 2008 for $1.7 billion in cash.
"Bruce is a highly accomplished leader with a proven record of developing medical products that help large numbers of patients," said Peyton Anderson, Affinergy's CEO. "I believe Bruce will be a transformative leader for Affinergy as we develop our own products and assess other technologies and companies to acquire. It is a great testament to our existing employees, partners, and investors that we can recruit a leader like Bruce to join Affinergy. We're delighted to welcome Bruce and his family to RTP as we continue building Affinergy into a product based company."
"Affinergy is uniquely positioned to develop exceptional products for a wide variety of patients and I find that personally exciting," said Dr. Lamb. "It is rare to find a young company with such talented people, a robust technology, excellent infrastructure, and a strong financial position. I share Affinergy's high expectations to become a large and profitable product company that directly benefits patients, employees, and shareholders. Our greatest challenge will be prioritizing the multiple opportunities."
Prior to Dr. Lamb's leadership role at LifeCell, Inc., he spent 6 years at Johnson & Johnson's Ethicon Division where he was VP, Worldwide Research & Development for Biosurgicals. Previously, he worked for Convatec for 7 years in increasing roles of responsibility within product development. Dr. Lamb began his career with 6 years at Pfizer's Hospital Products Group. He earned his Ph.D. in Polymer Chemistry at SUNY College of ESF, Syracuse. He earned his M.S. in Chemistry at the University of Wisconsin, Milwaukee and his B.S. in Chemistry at Bradley University.
About Affinergy, Inc.
Affinergy develops site-specific biological systems using biofriendly linkers that selectively adhere to proteins, drugs, cells, and biomaterial surfaces in order to kickstart biology toward an intended outcome. Affinergy is focused on developing coatings and medical devices for the orthopedic and cardiovascular markets. Affinergy's technology was patented at Duke University and was awarded 2005 Innovation of the Year by Frost & Sullivan in the category of Medical Device Coatings. For more information, visit www.affinergy.com.
For more information:
Peyton Anderson
Chief Executive Officer
Affinergy, Inc.
919-433-2229
panderson@affinergy.com
|
